STOCK TITAN

CYTOKINETICS (CYTK) EVP Andrew Callos sells 7,449 shares in open market

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.

Positive

  • None.

Negative

  • None.

Insights

Routine-sized open-market sale by a senior executive, with substantial holdings retained.

EVP and Chief Commercial Officer Andrew Callos executed an open-market sale of 7,449 shares of CYTOKINETICS INC Common Stock at $66.02 per share. The transaction is coded as an open-market sale, which is a discretionary move rather than a mechanical event like tax withholding.

After the sale, Callos still directly owns 58,555 shares, indicating he retains a significant equity position. The filing shows no derivative positions and no footnote disclosures about trading plans or indirect ownership in this excerpt. Based on the available data, this appears to be a routine insider sale rather than a transformative event.

Insider Callos Andrew
Role EVP, Chief Commercial Officer
Sold 7,449 shs ($492K)
Type Security Shares Price Value
Sale Common Stock 7,449 $66.02 $492K
Holdings After Transaction: Common Stock — 58,555 shares (Direct)
Footnotes (1)
Shares sold 7,449 shares Open-market sale of CYTOKINETICS INC Common Stock
Sale price $66.02 per share Price for the 7,449 shares sold
Shares held after transaction 58,555 shares Direct ownership by Andrew Callos following the sale
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
transaction code "S" financial
"transaction_code_description: "Sale in open market or private transaction""
direct ownership financial
"ownership_type: "direct""
net-sell financial
"netBuySellDirection: "net-sell""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Callos Andrew

(Last)(First)(Middle)
350 OYSTER POINT BLVD

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/15/2026S7,449D$66.0258,555D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ John O. Faurescu, attorney-in-fact for Mr. Callos04/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTK executive Andrew Callos report?

Andrew Callos reported an open-market sale of CYTOKINETICS INC (CYTK) Common Stock. He sold 7,449 shares at $66.02 per share, and the transaction was classified as a non-derivative, open-market sale under transaction code "S" in a Form 4 filing.

How many CYTK shares does Andrew Callos hold after this Form 4 sale?

After the reported sale, Andrew Callos directly holds 58,555 shares of CYTOKINETICS INC (CYTK) Common Stock. This post-transaction balance reflects his remaining direct ownership following the open-market sale of 7,449 shares disclosed in the Form 4.

At what price did Andrew Callos sell his CYTK shares in this filing?

Andrew Callos sold his CYTOKINETICS INC (CYTK) Common Stock at $66.02 per share. The Form 4 indicates an open-market transaction involving 7,449 shares of Common Stock at that price, classified under transaction code "S" for a sale in the open market.

What role does Andrew Callos hold at CYTOKINETICS INC (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at CYTOKINETICS INC (CYTK). His officer status is disclosed in the Form 4, where he reports a sale of 7,449 shares of Common Stock in an open-market transaction while retaining 58,555 shares afterward.

Was the CYTK insider transaction by Andrew Callos a buy or sell?

The transaction reported by Andrew Callos was a sell. The Form 4 classifies it as an open-market sale under transaction code "S," with 7,449 shares of CYTOKINETICS INC (CYTK) Common Stock sold at $66.02 per share, reducing but not eliminating his direct holdings.